An experimental MS therapy given as a nasal spray has started dosing its final participant in a Phase 2a trial of people with nonactive SPMS.
Initiating high-efficacy monoclonal antibody therapy before age 18 may reduce long-term disability in pediatric-onset multiple sclerosis.
MS trial is a randomized, double-blind, placebo-controlled Phase 2a trial using Intranasal Foralumab in patients with Non-Active Secondary Progressive Multiple Sclerosis BOSTON, June 25, 2026 (GLOBE ...
I am eager to see our ultimate goal realized—to change the lives of MS patients and future generations by identifying the cause of, and a cure for, this disease.” — Dr. Saud A. Sadiq, founder and ...
Researchers say ability to see for the first time previously hidden indicators of MS disease progression is an important advance.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results